Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Rajat Thawani1, Matteo Repetto2, Clare Keddy3
1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
NPJ Precision Oncology
|August 28, 2024
Abstract
No abstract available in PubMed .
Related Concept Videos
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


